DUSA Pharmaceuticals, Inc. To Host First Quarter Corporate Highlights And Financial Results Conference Call
Wilmington, MA. May 5, 2006 - DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA) announces that its first quarter corporate highlights and financial results press release will be issued on Wednesday, May 10 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Wednesday, May 10 - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
Password – DUSA
For International callers use
Password – DUSA
A recorded replay of the call will be available by 12:00 pm
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site after 1:00 p.m. www.dusapharma.com.
DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA’s other dermatology products include Nicomide®, and the AVAR® line, resulting from its recent merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA.
- Contact Information
- Shari Lovell
- Director, Shareholder Services
- DUSA Pharmaceuticals, Inc.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.